|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.
|
28871472 |
2017 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite several recent meta-analyses showing an association between several polymorphisms in genes related with detoxification mechanisms such as cytochrome P4502D6 (CYP2D6), and glutathione transferases M1 and T1 (GSTM1, and GSTT1), data on NAT2 gene polymorphisms obtained from the current meta-analysis do not support a major association with PD risk, except in Asian populations.
|
27216438 |
2016 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.
|
23258538 |
2013 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of polymorphism in cytochrome P450 2D6 and N-acetyltransferase-2 with Parkinson's disease.
|
20364044 |
2010 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate logistic regression analysis revealed that heterozygous genotypes of cytochrome P4502D6*4(CYP2D6*4), CYP2E1*5B (RsaI) polymorphism and homozygous mutant genotypes of CYP2E1*6 (Dra1) were found to be overrepresented in PD cases when compared to the controls.
|
18327668 |
2008 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also found that the cytochrome P450 2D6 gene could have a modifying effect on the risk of PD among persons exposed to pesticides.
|
17502288 |
2007 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease.
|
17270484 |
2007 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was conducted to examine the interaction between cytochrome p450 2D6: CYP2D6 (phase I) poor metabolizer (PM) and glutathione S-transferase M1: GSTM1 (phase II) null genotypes, among 103 unrelated French Parkinson's disease (PD) patients.
|
15061826 |
2004 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neurogenetic correlates of Parkinson's disease: apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism.
|
10353349 |
1999 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.
|
10210913 |
1999 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a case-control study to investigate the association of the poor metaboliser genotype of the cytochrome P450 2D6 gene with Parkinson's disease (PD).
|
9455978 |
1997 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease.
|
9316701 |
1994 |
|
Malignant neoplasm of breast
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Tamoxifen (TAM) is a frequently used hormonal prodrug for patients with breast cancer that needs to be activated by cytochrome P450 2D6 (CYP2D6) into Zusammen-endoxifen (Z-END).
|
30843495 |
2019 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Tamoxifen (TAM) is a frequently used hormonal prodrug for patients with breast cancer that needs to be activated by cytochrome P450 2D6 (CYP2D6) into Zusammen-endoxifen (Z-END).
|
30843495 |
2019 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
This study evaluated self-reported knowledge, practice, and attitudes toward commercially available cytochrome P450 2D6 (CYP2D6) pharmacogenomic testing for patients on tamoxifen for breast cancer (CYPT) among US oncologists while evidence for the use of the test was evolving.
|
23893861 |
2013 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
This study evaluated self-reported knowledge, practice, and attitudes toward commercially available cytochrome P450 2D6 (CYP2D6) pharmacogenomic testing for patients on tamoxifen for breast cancer (CYPT) among US oncologists while evidence for the use of the test was evolving.
|
23893861 |
2013 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
|
Malignant neoplasm of breast
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
To determine whether or not testing for cytochrome P450 2D6 (CYP2D6) polymorphisms in women with early hormone receptor positive breast cancer leads to improvement in outcomes, is useful for health decision-making and is a cost-effective use of health-care resources.
|
21906462 |
2011 |
|
Malignant neoplasm of breast
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI).
|
21430657 |
2011 |
|
Breast Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
|
Breast Carcinoma
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
To determine whether or not testing for cytochrome P450 2D6 (CYP2D6) polymorphisms in women with early hormone receptor positive breast cancer leads to improvement in outcomes, is useful for health decision-making and is a cost-effective use of health-care resources.
|
21906462 |
2011 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
We explored whether breast cancer outcomes are associated with endoxifen and other metabolites of tamoxifen and examined potential correlates of endoxifen concentration levels in serum including cytochrome P450 2D6 (CYP2D6) metabolizer phenotype and body mass index (BMI).
|
21430657 |
2011 |
|
Malignant neoplasm of breast
|
0.080 |
Biomarker
|
disease |
BEFREE |
Tamoxifen is extensively metabolized by cytochrome P450 enzymes, and recent in vivo studies have shown that women with genetically impaired cytochrome P450 2D6 have reduced production of endoxifen and a higher risk of breast cancer recurrence.
|
19244106 |
2009 |
|
Malignant neoplasm of breast
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
|
19421167 |
2009 |
|
Breast Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
|
19421167 |
2009 |